1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow John Sfakianos: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer Durvalumab, Monalizumab - Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Recruiting | John Sfakianos | 60 | 2025-02-24 | 2026-10-05 |
Non-Muscle Invasive Bladder Neoplasms (1)
durvalumab (1) · monalizumab (1)
United States (1)